These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 31612192)

  • 1. Assessment of response to therapy in multiple myeloma by multiparameter flow cytometry. Usefulness of an eight-color single tube with monoclonal antibodies in dried formulation.
    Carulli G; Tarasco A; Sammuri P; Ottaviano V; Domenichini C; Ciancia EM; Petrini M
    Clin Ter; 2019; 170(5):e352-e356. PubMed ID: 31612192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry.
    Sato K; Okazuka K; Ishida T; Sakamoto J; Kaneko S; Nashimoto J; Uto Y; Ogura M; Yoshiki Y; Abe Y; Maeda A; Hamazaki H; Tsukada N; Hiragohri Y; Suzuki K
    Ann Hematol; 2021 Dec; 100(12):2989-2995. PubMed ID: 34430990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry.
    Takamatsu H; Yoroidaka T; Fujisawa M; Kobori K; Hanawa M; Yamashita T; Murata R; Ueda M; Nakao S; Matsue K
    Int J Hematol; 2019 Apr; 109(4):377-381. PubMed ID: 30778767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma.
    Rossi G; Falcone AP; Minervini MM; De Cillis GP; De Waure C; Sisti LG; Giambra V; Valente D; Chiello V; Scalzulli PR; Carella AM; Cascavilla N
    Cytometry B Clin Cytom; 2019 May; 96(3):195-200. PubMed ID: 30549231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-Tube 10-Fluorochrome Analysis for Efficient Flow Cytometric Evaluation of Minimal Residual Disease in Plasma Cell Myeloma.
    Royston DJ; Gao Q; Nguyen N; Maslak P; Dogan A; Roshal M
    Am J Clin Pathol; 2016 Jul; 146(1):41-9. PubMed ID: 27402608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.
    Rawstron AC; Child JA; de Tute RM; Davies FE; Gregory WM; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Feyler S; Ross FM; Cook G; Jackson GH; Morgan GJ; Owen RG
    J Clin Oncol; 2013 Jul; 31(20):2540-7. PubMed ID: 23733781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Multiple myeloma: Maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual disease].
    Solovyev MV; Mendeleeva LP; Pokrovskaya OS; Nareyko MV; Firsova MV; Galtseva IV; Davydova YO; Kapranov NM; Kuzmina LA; Gemdzhian EG; Savchenko VG
    Ter Arkh; 2017; 89(7):25-31. PubMed ID: 28766537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study.
    Cordone I; Marchesi F; Masi S; Summa V; Pisani F; Merola R; Cigliana G; Orlandi G; Gumenyuk S; Palombi F; Romano A; Spadea A; Renzi D; Papa E; Canfora M; Conti L; Petti MC; Mengarelli A
    J Exp Clin Cancer Res; 2016 Mar; 35():49. PubMed ID: 26992692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.
    Paiva B; Chandia M; Puig N; Vidriales MB; Perez JJ; Lopez-Corral L; Ocio EM; Garcia-Sanz R; Gutierrez NC; Jimenez-Ubieto A; Lahuerta JJ; Mateos MV; San Miguel JF
    Haematologica; 2015 Feb; 100(2):e53-5. PubMed ID: 25381128
    [No Abstract]   [Full Text] [Related]  

  • 10. Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry.
    Belotti A; Ribolla R; Cancelli V; Villanacci A; Angelini V; Chiarini M; Giustini V; Facchetti GV; Roccaro AM; Ferrari S; Peli A; Bottelli C; Cattaneo C; Crippa C; Micilotta M; Frittoli B; Grazioli L; Rossi G; Tucci A
    Cancer Med; 2021 Sep; 10(17):5859-5865. PubMed ID: 34263564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
    Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of minimal residual disease in myeloma and the need for a consensus approach.
    Rawstron AC; Paiva B; Stetler-Stevenson M
    Cytometry B Clin Cytom; 2016 Jan; 90(1):21-5. PubMed ID: 26202864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
    Paiva B; Vidriales MB; Cerveró J; Mateo G; Pérez JJ; Montalbán MA; Sureda A; Montejano L; Gutiérrez NC; García de Coca A; de Las Heras N; Mateos MV; López-Berges MC; García-Boyero R; Galende J; Hernández J; Palomera L; Carrera D; Martínez R; de la Rubia J; Martín A; Bladé J; Lahuerta JJ; Orfao A; San Miguel JF;
    Blood; 2008 Nov; 112(10):4017-23. PubMed ID: 18669875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods.
    Yoroidaka T; Narita K; Takamatsu H; Fujisawa M; Nakao S; Matsue K
    Sci Rep; 2021 May; 11(1):11218. PubMed ID: 34045494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy.
    Mathis S; Chapuis N; Borgeot J; Maynadié M; Fontenay M; Béné MC; Guy J; Bardet V
    Cytometry B Clin Cytom; 2015 Mar; 88(2):101-9. PubMed ID: 25399680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data.
    Sharma P; Singh Sachdeva MU; Varma N; Bose P; Aggarwal R; Malhotra P
    J Cancer Res Ther; 2021; 17(6):1515-1520. PubMed ID: 34916387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term CR Multiple Myeloma Patients Show Cured or MGUS-like Minimal Residual Disease Pattern by Next Generation Flow.
    Gozzetti A; Pacelli P; Raspadori D; Bestoso E; Tocci D; Sicuranza A; Bocchia M
    Rev Recent Clin Trials; 2022; 17(2):92-96. PubMed ID: 35578845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
    Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
    BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Impact of minimal residual disease detection after treatment of multiple myeloma].
    Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
    Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study.
    Liu H; Yuan C; Heinerich J; Braylan R; Chang M; Wingard J; Moreb J
    Leuk Lymphoma; 2008 Feb; 49(2):306-14. PubMed ID: 18231918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.